What Quasym LP Treats: Main Uses and Benefits

Quasym LP, whose active substance is methylphenidate, is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 years and over and adolescents. It is used as part of a comprehensive treatment programme that includes psychological, educational, and social interventions. This treatment is applied when remedial measures alone prove insufficient for managing the symptoms that cause clinically significant impairment in a patient’s social, academic, or occupational functioning.

The therapeutic relevance involves symptoms related to inattention, excessive hyperactivity, and impaired impulse control. The medication is commonly used to help with symptom clusters that interfere with daily functioning and are relevant in conditions characterized by periods of heightened symptoms.

“The primary goal of this medication is to provide supportive relief that helps patients cope more steadily with the fluctuations of chronic, disruptive symptoms.”

This approach provides support that contributes to sustained attention and assists with concentration, and is also relevant for easing behaviors such as restlessness and actions taken without forethought. The long-acting design is applied in scenarios where additional supportive symptom management is appropriate throughout the entire school or work day, contributing to easing the overall symptom load and helps maintain functional stability in the patient's daily life.

---

Quick Fact: Symptomatic Support for Inattention, Hyperactivity, and Impulsivity Quasym LP is generally applied when core symptoms of ADHD become difficult to tolerate, and may involve a pharmacological intervention to assist with behavioral and cognitive regulation.

Regulatory References

1. European Medicines Agency in their assessment of methylphenidate-containing medicines

Who Can and Cannot Use Quasym LP?

The eligibility for Quasym LP (methylphenidate extended-release) is strictly defined by official regulatory documentation.

Approved and Restricted Populations

Quasym LP is officially approved for use in children aged 6 years and over and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). The medicine is not recommended for use in children younger than 6 years of age. For patients over 65 years of age, the safety and efficacy of this specific formulation have not been established in regulatory data.

Absolute Contraindications

The medicine is contraindicated (must not be used) for individuals with specific medical conditions, including:

• Pre-existing severe cardiovascular conditions, such as severe hypertension, heart failure, or certain arrhythmias.
• A history of motor tics or Tourette's syndrome.
• Conditions like glaucoma or phaeochromocytoma.
• Treatment with a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of discontinuing an MAOI.

Regulatory caution is explicitly advised for nursing mothers, and use during pregnancy is not recommended unless deemed necessary.

Interactions with other medicines and products

The official regulatory profile for Quasym LP, which contains methylphenidate, establishes several key restrictions regarding co-administered medicines and other substances.

Formal Prohibitions and Timing Rules

The co-administration of Quasym LP with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the documented risk of a hypertensive crisis. A mandatory separation period of at least 14 days must pass after discontinuing an MAOI before beginning treatment. Furthermore, use must be avoided on the day of surgery if Halogenated Anesthetics are to be administered, owing to the documented risk of marked increases in heart rate and blood pressure.

Pharmacokinetic and Pharmacodynamic Interactions

Methylphenidate may inhibit the metabolism of certain agents, leading to an increase in their plasma concentration and overall exposure. This pharmacokinetic interaction pattern is documented for specific medicines, including Coumarin Anticoagulants, certain Anticonvulsants (such as Phenobarbital and Phenytoin), and Tricyclic Antidepressants. The pressor effects of the medicine may also decrease the effectiveness of co-administered Antihypertensive Drugs.

Substance and Formulation Constraints

Due to the medicine's long-acting, modified-release design, the consumption of alcohol (ethanol) must be avoided, as it may cause a rapid release (dose dumping) of the active substance. Some regulatory information also notes that substances that reduce gastric acid, such as Proton Pump Inhibitors (PPIs) or H2-antagonists, may interfere with the controlled-release properties of the formulation.

Targeting Neurotransmitter Reuptake

The mechanism begins at the synapse, where the active compound, methylphenidate, functions as an inhibitor of the Dopamine Transporter (DAT) and Norepinephrine Transporter (NET). By physically blocking these transporters, the drug prevents the reabsorption of dopamine and norepinephrine back into the presynaptic neuron, thereby increasing and prolonging the concentration of these catecholamines in the synaptic cleft.

---

Modulating Signaling in Executive Circuits

The resulting increase in synaptic catecholamines specifically modulates signaling in the Prefrontal Cortex (PFC), a brain region involved in executive cognitive function. This mechanistic cascade modulates the neuronal Signal-to-Noise Ratio, which is the physiological basis for improved processing of relevant information. This enhanced signaling alters the activity within attentional and behavioral pathways, producing specific physiological consequences consistent with the drug's mechanism.

---

Constraints of the Mechanistic Effect

Quasym LP's effect is maintained by an engineered release mechanism that provides continuous inhibition of the DAT and NET. However, the efficacy of this mechanism is inherently dependent on basal neurotransmitter release; if the underlying dopaminergic activity is too low, the drug’s amplification effect is physiologically constrained, resulting in less potent modulation of synaptic levels.

How to Use Quasym LP (Methylphenidate Modified-Release Capsule)

This medication is a methylphenidate modified-release capsule, which contains an immediate-release component (approximately 30% of the dose) and a modified-release component (approximately 70%) to provide a twice-daily dosing profile in a single morning capsule. Quasym LP should be used only as directed by a healthcare specialist.

Administration Scope	Official Instruction
Route of Administration	Oral use only.
Dosing Frequency	Once daily in the morning.
Timing in Relation to Meals	Must be taken before breakfast.
Age Group	Indicated for patients 6 years of age and over (children and adolescents).

Procedural Requirements

1. Swallowing the Capsule: The capsule must be swallowed whole with a liquid.
2. Alternative Administration: If swallowing whole is difficult, the capsule may be opened, and all of its contents (sprinkles/beads) may be sprinkled onto a small amount (e.g., a tablespoon) of soft food, such as applesauce. The mixture must be swallowed immediately and followed by a drink; it must not be stored for later use.
3. Handling Restriction: The capsule and its contents must not be crushed or chewed at any time. Chewing or crushing the contents will destroy the modified-release properties and result in the rapid release and absorption of all medication.

Dosing Guidance

The maximum recommended daily dose is 60 mg. Dosage should be determined individually based on patient response and may be gradually adjusted over time. The continued usefulness of the medication should be re-evaluated periodically by the prescribing physician.

Quasym LP: Recent Clinical Evidence

Mechanism of Action

Research has explored the mechanism of action for the compounds in Quasym LP, suggesting they may interact with pathways in both the peripheral and central nervous system. The studies evaluated whether this interaction could influence pain perception, noting the dual pathway involvement.

---

Clinical Trial Results

Phase 2 Efficacy and Dosing

Initial Phase 2 studies explored the impact on patient-reported pain scores, and some studies reported a change in these scores. These early trials focused primarily on establishing the safety profile and identifying dosage ranges.

Long-Term Outcomes (12 Weeks and Beyond)

A large-scale Phase 3 trial reported outcomes related to measures of chronic neuropathic pain over a 12-week period.

---

Comparative Studies

The findings from specific studies were compared to outcomes observed with monotherapy (a single drug treatment). It is not yet clear whether the Quasym LP regimen results in a different effect than monotherapy.

---

Safety and Tolerability

Side Effect Profile

Common side effects reported in the studies include mild drowsiness and dry mouth. The study reports described the resolution of these events in some participants. Gastrointestinal discomfort was also noted as an occurrence in the study groups. The studies did not evaluate the effects of abruptly stopping the medication. Trial discontinuation rates due to adverse events were recorded.

Special Populations

The research included an analysis of outcomes in elderly patients. Dosage was also evaluated in patients with mild-to-moderate renal impairment.

Key Studies & References

1. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Cochrane Systematic Review)

How to Store and Dispose of Quasym LP?

The storage and disposal of Quasym LP (methylphenidate) must strictly follow official regulatory requirements to ensure product stability and prevent accidental exposure or misuse.

---

Storage Requirements

The medication must be stored at a controlled room temperature, between 20°C and 25°C (68°F to 77°F). It must be kept in the original container with the cap tightly closed and protected from moisture.

• Child Safety: Due to the potential for abuse, Quasym LP must be stored in a safe, often locked, location and kept out of the sight and reach of children.
• Stability: If the capsule contents are mixed with food, the mixture must be consumed immediately and cannot be stored for later use.

---

Official Disposal Rules

Disposal should ideally occur through a drug take-back program or an authorized collector site. If a take-back option is unavailable, the U.S. FDA recommends flushing the unused medication down the toilet to mitigate the serious risk of accidental ingestion or diversion associated with the controlled substance.